Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

ASND – Ascendis Pharma A/S

Ascendis Pharma A/S
ASND
$221.49
Name : Ascendis Pharma A/S
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $13,532,631,040.00
EPSttm : -4.53
finviz dynamic chart for ASND
Ascendis Pharma A/S
$221.49
1.14%
$2.56

Float Short %

4.79

Margin Of Safety %

Put/Call OI Ratio

0.34

EPS Next Q Diff

1.62

EPS Last/This Y

4.36

EPS This/Next Y

7.26

Price

221.1

Target Price

274.44

Analyst Recom

1.22

Performance Q

13

Relative Volume

1.36

Beta

0.43

Ticker: ASND




21 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-13ASND214.960.270.0519848
2026-01-14ASND217.50.260.4720173
2026-01-15ASND215.250.260.0020269
2026-01-16ASND205.690.272.9519639
2026-01-20ASND215.280.280.1212088
2026-01-21ASND216.780.310.7212695
2026-01-22ASND228.670.310.4212727
2026-01-23ASND235.410.320.4413126
2026-01-26ASND233.820.330.0213992
2026-01-27ASND238.720.320.1014323
2026-01-28ASND222.430.320.3814393
2026-01-29ASND223.60.330.1714642
2026-01-30ASND225.990.341.1514599
2026-02-02ASND223.370.340.2914610
2026-02-03ASND224.780.341.0714614
2026-02-04ASND219.670.350.2915001
2026-02-05ASND217.70.351.1015006
2026-02-06ASND222.230.352.5215011
2026-02-09ASND222.470.340.1014942
2026-02-10ASND224.220.340.6714988
2026-02-11ASND221.430.340.2415000
DateSymbolLatestP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-13ASND215.0479.0388.0-3.22
2026-01-14ASND217.4472.2383.9-3.22
2026-01-15ASND215.2772.2379.4-3.22
2026-01-16ASND205.7670.0372.5-3.22
2026-01-20ASND215.4563.9391.1-3.22
2026-01-21ASND216.7658.1382.2-3.22
2026-01-22ASND228.6458.1392.6-3.22
2026-01-23ASND235.3156.7387.1-3.22
2026-01-26ASND233.8156.7379.6-3.22
2026-01-27ASND238.7756.7385.6-3.22
2026-01-28ASND222.4556.7366.7-3.22
2026-01-29ASND223.8462.1382.5-3.22
2026-01-30ASND225.8062.1383.1-3.22
2026-02-02ASND223.3461.7378.9-3.22
2026-02-03ASND224.5561.7385.3-3.22
2026-02-04ASND219.9561.7- -3.22
2026-02-05ASND217.6061.7- -3.22
2026-02-06ASND222.2661.7- -3.22
2026-02-09ASND222.0761.7- -3.22
2026-02-10ASND224.1561.7- -3.22
2026-02-11ASND221.1061.7- -3.22
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-13ASND0.001.785.71
2026-01-14ASND0.001.785.71
2026-01-15ASND0.001.785.71
2026-01-16ASND0.001.785.71
2026-01-20ASND0.001.605.71
2026-01-21ASND0.001.605.71
2026-01-22ASND0.001.605.71
2026-01-23ASND0.001.605.71
2026-01-26ASND0.002.055.71
2026-01-27ASND0.002.055.71
2026-01-28ASND0.002.055.23
2026-01-29ASND0.002.055.23
2026-01-30ASND0.002.055.23
2026-02-02ASND0.002.045.23
2026-02-03ASND0.002.045.23
2026-02-04ASND0.002.045.23
2026-02-05ASND0.002.045.23
2026-02-06ASND0.002.045.23
2026-02-09ASND0.001.015.23
2026-02-10ASND0.001.015.23
2026-02-11ASND0.001.014.79
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-1.17

Avg. EPS Est. Current Quarter

-0.14

Avg. EPS Est. Next Quarter

0.45

Insider Transactions

Institutional Transactions

1.01

Beta

0.43

Average Sales Estimate Current Quarter

245

Average Sales Estimate Next Quarter

281

Fair Value

Quality Score

33

Growth Score

56

Sentiment Score

34

Actual DrawDown %

8.6

Max Drawdown 5-Year %

-60.5

Target Price

274.44

P/E

Forward P/E

48.88

PEG

P/S

18.78

P/B

P/Free Cash Flow

EPS

-4.25

Average EPS Est. Cur. Y​

-3.22

EPS Next Y. (Est.)

4.04

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.52

Relative Volume

1.36

Return on Equity vs Sector %

106

Return on Equity vs Industry %

122.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.17

EBIT Estimation

Ascendis Pharma A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 1017
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading